Search Results - "Diolez, Jéremie"
-
1
Pilot Pharmacokinetic Study of High-Dose Daptomycin in Hemodialysis Patients With Infected Medical Devices
Published in American journal of kidney diseases (01-11-2017)Get full text
Journal Article -
2
Carfilzomib weekly 20/56 mg/m2, lenalidomide and dexamethasone for early relapsed refractory multiple myeloma
Published in American journal of hematology (01-01-2019)Get full text
Journal Article -
3
Carfilzomib weekly 20/56 mg/m 2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma
Published in American journal of hematology (01-01-2019)Get full text
Journal Article -
4
Profile of Long-Term Survivors in Multiple Myeloma
Published in Blood (13-11-2019)“…Background: The treatment revolution of multiple myeloma (MM) with the advent of novel therapies, proteasome inhibitors, immunomodulators and newer drugs lead…”
Get full text
Journal Article -
5
Carfilzomib Weekly 20/56mg/m², Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma
Published in Blood (29-11-2018)“…Background. Triplet-based lenalidomide plus dexamethasone combinations have become the new standard of care for early RRMM, including with carfilzomib (KRd)…”
Get full text
Journal Article -
6
Chronic HCV Infection and Autologous Stem Cell Transplantation for Multiple Myeloma
Published in Blood (29-11-2018)“…Introduction. The pronostic of Chronic hepatitis C (Hep C) has transformed towards cure in recent years with the advent of the antiviral treatment by…”
Get full text
Journal Article -
7
Pomalidomide 3rd Line Versus 4th Line for RRMM
Published in Blood (08-12-2017)“…Background. Pomalidomide in association with dexamethasone is approved for RRMM in 3rd line and beyond based on the multicenter international phase 3MM-003…”
Get full text
Journal Article -
8
Carfilzomib Weekly 20/56mg/m², Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma
Published in Blood (08-12-2017)“…Background. Triplet-based lenalidomide plus dexamethasone combinations have become the new standard of care for early relapse and refractory multiple myeloma…”
Get full text
Journal Article